Ginkgo biloba: reduced efficacy of efavirenz.
D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects*; D048588:Benzoxazines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D001711:Biotransformation; D003521:Cyclopropanes; D020441:Ginkgo biloba; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D041743:Herb-Drug Interactions; D006801:Humans; D008875:Middle Aged; D061214:Patient Safety; D010936:Plant Extracts / Q000009:adverse effects*; D018894:Reverse Transcriptase Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018570:Risk Assessment; D012307:Risk Factors; D019562:Viral Load
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010936:Plant Extracts; D018894:Reverse Transcriptase Inhibitors; C098320:efavirenz